The trial enrolled patients with cystic fibrosis and chronic pulmonary Pseudomonas aeruginosa infection. Credit: Paulo Henrique Orlandi Mourao / commons.wikimedia.org.

Armata Pharmaceuticals has concluded the Phase Ib/IIa clinical trial of its lead candidate, AP-PA02, in cystic fibrosis (CF) patients with chronic pulmonary Pseudomonas aeruginosa infection.

Named SWARM-P.a., the double-blind, multicentre, placebo-controlled, randomised, single ascending dose (SAD) and multiple ascending dose (MAD) trial is designed to assess the safety and tolerability of inhaled AP-PA02.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It enrolled patients with CF and chronic pulmonary Pseudomonas infection. 

The trial was carried out by Armata in partnership with the Cystic Fibrosis Therapeutics Development Network (TDN).

Topline findings from the trial are expected in the first quarter of next year.

See Also:

Armata received $5m in funding for therapeutic development from the CF Foundation to progress AP-PA02’s development, in March 2020.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

To offer additional support for the development of the candidate, the foundation made an equity investment of $3m in Armata in October last year.

Armata Pharmaceuticals CEO Dr Brian Varnum said: “The completion of SWARM-P.a. represents a critical milestone for our lead programme and for Armata. 

“This trial will provide critical information regarding inhaled delivery of phage, importantly, assessment of safety and tolerability of phage therapy in the CF population. 

“Additionally, this first-in-human Phase Ib/IIa study will provide critical insights for dosing paradigms required to meet microbiological endpoints.” 

In August this year, the company received clearance for the Investigational New Drug (IND) application for AP-SA02 in prosthetic joint infection (PJI) from the US Food and Drug Administration (FDA).

The development enabled Armata to plan commencement of the Phase Ib/IIa trial to evaluate the safety, tolerability and pharmacokinetics of intravenous and intra-articular doses of AP-SA02 as an adjunct to standard of care antibiotics in patients with PJI.